| INTRODUC TI ON
In CRC development, inactivation of the APC gene often occurs as the initial event in development of preneoplastic asymptomatic lesions known as adenomatous polyps. The step-wise accumulation of genetic alterations confers a malignant phenotype that leads to carcinoma formation. Comprehensive sequence analysis has revealed the genomic landscapes of human cancer, 1 which support the notion that alterations in key pathways, including Wnt signaling and RAS signaling, play critical roles in the initiation and progression of CRC development. Recently, this model of CRC development was biologically validated by application of genome-editing technology to organoid culture derived from the human colon. 2, 3 FAP is an autosomal-dominant inherited disease caused by germline mutations in the APC gene. 4 The second hit causes adenomatous polyps, which recapitulates the initial event of sporadic CRC development. According to the number of polyps and the age of onset, diagnosis is often difficult. It has been reported that the phenotypic difference between CFAP and AFAP is correlated with the germline mutation profiles of APC genes, 5, 6 but their biological significance has not been fully understood.
In this study, we established 42 organoids from five FAP patients. Multiple organoids derived from the same patients enable us to explore the effects of somatic mutations under isogenic conditions. Importantly, these structures also supply the opportunity to investigate the biological significance of individual genetic backgrounds by elucidating the differences in organoid sets derived from identical patients. In this work, we show that the attempt to identify the molecular basis of phenotypic differences between CFAP and AFAP reveals the outcomes of the genetic variation in tumor-formation potential and the response to chemotherapeutic agents. 1 μg/mL R-spondin-1 (R&D system, Minneapolis, MN, USA) and were maintained at 37°C at 5% O 2 . Media were changed every 3 days.
| MATERIAL AND ME THODS

| FAP organoid culture
To prepare Noggin conditioned medium, human Noggin cDNA was cloned into the pFK5K CMV-neo vector (Promega, Fitchburg, MN, USA) and expressed in L1 cells. Transfected cells were selected with 800 μg/mL G418 and were screened with the Dual-Luciferase
Assay system (Promega) using BRE-MLP-Luc as a reporter. 7 Conditioned medium was prepared by culturing Noggin-expressing L1 cells in basal medium for 4 days. The activity of these cells was determined using the luciferase assay.
| Sequence analysis
Organoids were collected in cell recovery solution (Corning, Corning, NY, USA). Genomic DNA was extracted with the QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA), and the DNA quality was analyzed using the Qubit system (Thermo Fisher Scientific). An amount of 200 ng of genomic DNA was used in library construction via the HaloPlex kit (Agilent, Santa Clara, CA, USA), according to the manufacturer's instructions. Target genes were selected based on reported recurrent gene mutations. 8, 9 A list of target genes is given in Table S1 . Sequencing was performed by on the MiSeq system (Illumina, San Diego, CA, USA).
Fastq files were mapped and analyzed using SureCall (Agilent). APC variants were culled by removing those registered in the Human Genetic
Variation Database (HGVD release version 2.30). Other variants were annotated with ANNOVAR (2015-03-22 released). 10 The variants were excluded from the following analysis when maximal population frequency is over 1%. We excluded somatic missense SNVs with the following properties; (a) variants were neither deposited on COSMIC (ver82 https://cancer.sanger.ac.uk/cosmic/), (b) any variant fraction of the same patients does not exceed 0.25 (subclonal mutations).
| Microarray analysis
Organoids were collected in cell recovery solution (Corning), and RNA was extracted using the RNeasy Micro Kit (Qiagen). RNA quality was validated using an Agilent Bioanalyzer. An amount of 100 ng of RNA was used to prepare cRNA using the 3′ IVT PLUS Reagent Kit (Affymetrix, Santa Clara, CA, USA), and the cRNA was hybridized on a U133 Plus 2.0 Array (Affymetrix). GSEA was performed to explore the association of the expression profile of each patient with the Molecular Signature Database (http://software.broadinstitute.
org/gsea/index.jsp). Genes that were differentially expressed (>1 .6 fold) between CFAP and AFAP organoids were selected using Gene Spring Software, and the associated signaling pathways were identified using Ingenuity Pathway Analysis (Qiagen).
To investigate chromosomal aberrations, genomic DNA was extracted with the QIAamp DNA Mini Kit (Qiagen), and the quality of the DNA was analyzed on a NanoDrop instrument (Thermo Fisher Scientific). A total of 500 ng of gDNA was hybridized to the GenomeWide SNP 6 microarray (Affymetrix). CNVs and chromosomal aberrations in the APC gene were identified using Chromosome Analysis Suite (Affymetrix).
| Viability assay
One day before plating into 384 plates, the media was changed to ENR medium supplemented with 10 μmol/L Y27632 (Sigma).
Organoids were digested in TrypLE Express (Thermo Fisher 
| Immunoblot analysis
Organoids were collected using a cell recovery solution (Corning) and washed with PBS, and proteins were extracted using 1% NP-40 buffer (20 mmol/L Tris-HCl, pH 8.0, 137 mmol/L NaCl, 1% NP-40, 10% glycerol). The protein concentrations were determined using a protein assay (Bio-Rad, Hercules, CA, USA), and equal amounts of protein were resolved, transferred to nitrocellulose membranes and detected as previously described. 11 The antibodies used for the immunoblot analysis were as follows: anti-STAT1(D1K9Y, Cell Signaling), anti- 
| Genome editing of FAP organoids
sgRNA-expressing constructs were prepared by cloning a pair of annealed oligonucleotides into the BbsI site of pX330 (Addgene, Watertown, MA, USA). The oligonucleotides were designed based on a 20 bp target sequence (Table S2) . One day before electroporation, the media was changed to ENR medium supplemented with 10 μmol/L (Table S2) and was confirmed by immunoblot analysis using anti-STAT1 antibody.
| Genome editing and analysis of mouse intestines
All animal studies and procedures were approved by the JFCR Cancer
Institute Animal Care and Welfare Committee. Apc fl/fl , Lgr5-CreERT2 mice were generated as previously described. 11 Oocytes were obtained from Apc fl/fl , Lgr5-CreERT2 females undergoing superovulation treatment 13 and were used to generate Apc fl/fl , Lgr5-CreERT2 embryos using sperm from male Apc fl/fl , Lgr5-CreERT2 mice. A pair of oligonucleotides targeting exon 3 of the mouse Stat1 gene (Table   S2 ) was annealed and cloned into the BsaI site of pDR274 (Addgene).
The sgRNAs were prepared using the MEGAshortscript T7 Kit (Invitrogen). Amounts of 200 μg/mL sgRNA and 50 ng/mL Cas9 protein (TAKARA, Shiga, Japan) were introduced into the zygotes by electroporation as previously reported. 14 The presence of a 2-bp deletion in exon 3 of STAT1 in founder mice was confirmed by PCR amplification of the targeted region followed by Sanger sequencing, and these mice were used to generate homozygous mutants. Mice carrying wild-type STAT1, which were generated by intercrossing founder mice, were used as controls. Potential off-target sites predicted by Cas-OFFinder (http://www.rgenome.net/cas-offfinder/)
were amplified by PCR and analyzed by Sanger sequencing.
To analyze intestinal tumors, the intestine was removed and fixed in 10% neutral formalin (Wako, Tokyo, Japan) for 24 hours, and the Swissroll was prepared and embedded in paraffin following recently reported procedures. 15 Four-micron sections were mounted on MAS-coated slides (Matsunami, Tokyo, Japan) and stained with H&E for histological analysis or used for immunohistochemistry. After dewaxing and rehydration via a standard procedure, antigen retrieval was performed either by autoclaving in citrate buffer (pH 6.0) or by using the immunosaver 
| Mouse xenograft experiments
Organoids were dissociated into single cells by incubation in TrypLE at 37°C for 15 minutes, and clumps were removed by passing through a 40 μmol/L cell strainer. A total of 1 × 10 5 cells were resuspended in 50% Matrigel in ENR medium and subcutaneously injected into 6-to 7-week-old female NOD/SCID IL2Rγ − (NSG) mice using an insulin syringe. The animals were anesthetized with a combination of medetomidine, midazolam and butorphanol.
| RE SULTS
| Establishment of FAP organoids
Numerous adenomatous lesions occur in the colorectal region of FAP patients. Each lesion independently arises via the second hit of APC gene as an initiating event and proceeds to tumor development. As a result, these lesions harbor different sets of somatic mutations in an identical genetic background, which supply a valuable resource for genetic and biological analysis. Therefore, we independently cultured organoids derived from surgically resected adenomatous polyps from five FAP patients (Table S3 ). Three patients, HCT19, 20 and 24, had surgery prior to age 35 and were diagnosed with CFAP, and two patients, HCT14 and 23, underwent surgery after age 60 and were diagnosed with AFAP. Notably, patient HCT24 underwent the first surgery at age of 18 and exhibited the most severe phenotype. Organoids were readily established from both types of FAP tumors, and no significant difference between CFAP and AFAP was noted in the organoid establishment success rate (average 84%) ( Table S4) (Table S3) .
However, one organoid, HCT24-8, did form a tumor (Table S3) . Because all four transplanted grafts developed tumors, HCT24-8 possessed the intrinsic tumor formation potential rather than acquired tumor formation potential during the assay. These observations demonstrated that the FAP organoid set represents various stages ranging from benign tumors to malignant tumors and recapitulates the development of CRC.
| Genomic characterization of FAP organoids
The genetic aberrations in each organoid were determined via targeted sequence analysis (Figure 1) . 8, 9 APC alteration was detected in all organoids, and no pathological MUTY mutation was noted, indicating that the organoid sets are derived from APC-associated FAP patients ( Figure 1A ). The organoids derived from HCT19 and HCT23 mutations. 16 The S89* mutation in HCT23 and the large deletions in the APC gene in HCT14 were detected in normal blood samples, confirming their germline mutations.
In our analysis, an APC germline mutation was not identified in HCT20. Instead, a mutation in MSH6 was found in this patient, suggesting the possibility that this patient could be affected by HNPCC or Lynch syndrome. It should be noted, however, that the allele frequencies of this mutation were between 0.423 and 0.531, suggesting a heterozygous mutation (Table S5) . With regard to the family history of HCT20, her mother and her aunt were diagnosed with FAP-associated colon cancer. As for her previous history, she underwent a total colectomy with ileo-rectal anastomosis because of multiple colon polyps at the age of 32. Follow-up colonoscopy revealed multiple polyps and concomitant early cancer in the residual rectum at the age of 50 ( Figure S2A-C) . Additional upper gastrointestinal endoscopy showed multiple fundic gland polyps in the stomach ( Figure   S2D ). These clinical features support the FAP diagnosis for HCT20.
Second-hit mutations in the APC gene were identified, four of which were loss-of heterozygosity (LOH) mutations ( Figure 1A) .
Notably, distinct second-hit mutations were detected in each organoid, except for HCT24-10 and -11. Given that second hits in the APC gene occur as an initial event in tumorigenesis, these organoids were thought to arise independently.
It is well established that activation of KRAS is an early event in CRC progression, and in our organoid sets, four organoids harbored the activating mutation of KRAS ( Figure 1C) . No genetic alterations such as TP53, PIK3CA or SMAD4 were detected, which were believed to occur at a relatively late stage in the tumor progression.
Notably, these mutation frequencies were apparently lower than those reported in CRC. 8 These observations further support the notion that FAP organoids represent early events in CRC development. Figure 2B and Figure S3 ).
To further clarify the differences, we compared AFAP and CFAP and found striking differences in interferon gamma response (normalized enrichment score (NES) = −1.91, nominal P-value (NOM P < 0.01), interferon alpha response (NES = −1.88, NOM P < 0.01), IL6_JAK_STAT3 signaling (NES = −1.72, NOM P < 0.01) and allograft rejection gene sets (NES = −1.69, NOM P < 0.01) (Table S6 ).
AFAP was negatively correlated and CFAP was positively correlated with these gene sets ( Figure 2C ). Furthermore, Ingenuity Pathway Analysis (IPA) identified interferon signaling as the most statistically significant pathway (Z score = 3.606, P = 1.64E−6) ( Figure 2D ), supporting the results of GSEA. CFAP organoids exhibited higher expression of the transcription factor STAT1 (2.1-fold) and its target genes, including IFI6 (9.8-fold), IFIT3 (6.6-fold), MX1 (5.7-fold) and ISG15 (2.6-fold) ( Figure 2E , Table S7 ). Taken together, these observations demonstrated a striking association between the IFN/STAT signaling and the clinical features of FAP.
| Loss of IFN/STAT signaling leads to reduced tumor-forming potentials
The comparative gene expression analysis between CFAP and AFAP demonstrated a correlation between the tumor formation potentials and IFN/STAT signaling. We evaluated the functional relevance using a mouse model of FAP. The sgRNAs were designed to target exon3 of Stat1, and genome editing was conducted in zygotes carrying a homozygous conditional Apc allele (Apc fl/fl ) and an Lgr5-CreERT2 allele ( Figure 3A) . We obtained mutant mice carrying bi-allelic 2 bp deletions (Stat1 null/null ), and this deletion led to a frame-shift following the N-terminal 26 amino acids ( Figure S4 ). No off-target mutations were detected (Table S8 ). Stat1 was highly expressed in intestinal tumors induced via disruption of the Apc gene, whereas Stat1 null/null mice completely lost Stat1 expression, confirming the bi-allelic disruption of the Stat1 gene ( Figure 3B ). Importantly, the tumor area, determined by scoring β-catenin accumulation ( Figure S5 ), was significantly reduced in the intestines of Stat1-deficient animals (N = 6, P < 0.01, t-test) ( Figure 3C ). Lgr5 was strongly expressed in the lower regions and gradually decreased toward the upper domain of the lesion ( Figure   S6 ), indicating stem cell expansion in response to Apc inactivation.
Stat1 disruption did not alter the cellular composition of the lesion or the frequency of apoptosis, but it reduced the number of both Lgr5-positive and Lgr5-negative cycling cells (27.8% vs. 20.8%, P < 0.05, and 43.6% vs. 34.2%, P < 0.01, t-test, respectively) ( Figure 3D and E).
These observations demonstrated the functional relevance of IFN/ STAT signaling in the clinical features of FAP patients. However, phosphorylation of Tyr701 was minimally detected in these organoids. Instead, we observed elevated phosphorylation at Ser727, which is mediated by the ERK family of protein kinases. 23, 24 Similar observations were made in HCT19-7, which was derived from a CFAP patient and harbored a KRAS mutation ( Figure S7 ).
| IFN/STAT signaling is elevated in RAS-activated organoids
Interestingly, immunohistochemical analysis revealed that STAT1
was highly expressed in the HCT24-8 xenograft tumor, and phosphorylation of Ser727 but not Tyr701 was detected ( Figure 4D , Figure S8 ). Furthermore, STAT1 protein phosphorylate at Ser727 was accumulated in the nucleus. These observations support the notion that the activating mutation of KRAS enhanced IFN/STAT signaling by phosphorylation of the STAT1 protein.
| IFN/STAT signaling confers resistance to MEK inhibitors in KRAS mutant organoids
The analysis described above suggested that IFN/STAT signaling stimulated cell proliferation as a downstream target of RAS. We tested this hypothesis using chemotherapeutic agents targeting RAS signaling. As expected, the EGFR inhibitor gefitinib effectively reduced the viability of FAP organoids, but the activating mutation of KRAS conferred resistance ( Figure 5A ). In contrast, downstream perturbation of RAS by the MEK inhibitor trametinib reduced the viability of organoids harboring KRAS mutations (HCT14-9 and HCT20-6) ( Figure 5B ). However, unexpectedly, two other KRASmutated organoids, HCT19-7 and HCT24-8, were resistant to We examined whether trametinib inhibited RAS signaling in resistant organoids because accumulating evidence indicates that cancer cells acquire resistance to MEK inhibitors through persistent RAS signaling. [25] [26] [27] However, trametinib efficiently inhibited phosphorylation of ERK in HCT24-8 and -8x, and no persistent RAS signaling was observed ( Figure S10 ). We next focused on the correlation between sensitivity to MEK inhibitors and the IFN/STAT signaling because the two resistant clones were derived from CFAP and the sensitive clones were derived from AFAP. Since organoids derived from CFAP expressed higher STAT1 levels than those derived from AFAP and since unphosphorylated STAT1 has been reported to transduce the signaling, 28 this correlation raised the possibility that high STAT1 expression conferred the resistance to MEK inhibitors. To test this hypothesis, we disrupted STAT1 in HCT24-8 and examined the change in the response to MEK inhibitors. Using the CRISPR/Cas9 system, we obtained HCT24-8-STAT1KO cells harboring a bi-allelic 38 bp deletion, which resulted in a frame shift after the N-terminal 15 amino acids ( Figure S11A ). 12 Complete loss of STAT1 protein was confirmed by immunofluorescence analysis and immunoblot analysis ( Figure 6A , Figure S11B and C). As expected, GSEA analysis identified
Interferon alpha and gamma response as the gene sets most correlated with the STAT1 disruption (NES = 1.76, NOM P < 0.001 and NES = 1.48, NOM P = 0.004, respectively) ( Figure 6B and Table S9 ).
We examined the drug response of HCT24-8 STAT1KO and found that disruption of STAT1 did not affect the response to gefitinib but significantly restored the sensitivity to trametinib ( Figure 6C ).
Immunoblot analysis revealed that disruption of STAT1 did not affect the inhibition of ERK phosphorylation by MEK inhibitors, indicating that the effect of STAT1 disruption was independent of ERK activity ( Figure S12 ). Taken together, these observations demonstrated that high intrinsic IFN/STAT signaling activity confers resistance to MEK inhibitors in RAS-activated FAP organoids ( Figure 6D ). end of APC gene within exon9 or at the 3′ distal end of the gene. 17, 18 More recently, large inron14 rearrangement 19 and point mutations at the first 15-AA repeats have been shown to be associated with AFAP. 20 However, in our cohort, these phenotype-genotype correla- 30 This discrepancy may indicate that Stat1 plays specific roles in stem-cell expansion, as we used Lgr5-CRE ERT2 to disrupt the Apc gene to make a specific disruption in crypt base columnar cells. Alternatively, the phenotype could be due to allele differences, as the armadillo repeats were retained in the Apc min allele, while they were disrupted in the Apc 580D allele, which was generated from the noted that a difference between CFAP and AFAP was not observed in those carrying wild-type KRAS (Figure 5 ), suggesting that activated KRAS plays roles in trametinib sensitivity ( Figure 6D ). We have noticed that the phosphorylation of Ser724 of STAT1 in KRAS-activated organoid was not inhibited by trametinib ( Figure S13 ), suggesting that other kinases compensate for MEK activity. Several kinases, including mTOR, PKC and p38, have been reported to phosphorylate Ser727 of STAT1. Since these kinases are controlled, at least in part, by RAS, but are independent of MEK activity, they can potentiate trametinib resistance in CFAP organoids. 23 Alternatively, indirect crosstalk between the RAS and IFN/STAT signaling pathways may contribute to the differences in trametinib sensitivity between CFAP and AFAP. For instance, RAS phosphorylates BAD to control IFN/STAT-mediated apoptosis. 34 Further investigation is needed to gain mechanistic insight into the differences in trametinib sensitivity.
| D ISCUSS I ON
In this study, we have found that IFN/STAT singling enhances nations. 36 Our findings might offer a rationale for the stratification of patients and for the development of combination therapies including both MEK inhibitors and agents that perturb IFN/STAT signaling.
